43,598 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 43,598 shares of the medical equipment provider’s stock, valued at approximately $3,753,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Syon Capital LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $211,000. NEOS Investment Management LLC boosted its stake in shares of Zimmer Biomet by 5.0% in the second quarter. NEOS Investment Management LLC now owns 32,185 shares of the medical equipment provider’s stock worth $2,771,000 after buying an additional 1,529 shares during the last quarter. Nykredit A S purchased a new stake in shares of Zimmer Biomet in the second quarter worth about $3,419,000. Quantitative Investment Management LLC acquired a new stake in Zimmer Biomet during the second quarter worth about $1,008,000. Finally, Moore Capital Management LP purchased a new position in Zimmer Biomet during the second quarter valued at approximately $17,101,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $97.94 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $106.88. The business’s 50 day moving average is $94.82 and its two-hundred day moving average is $91.64. The company has a market capitalization of $18.68 billion, a P/E ratio of 23.83, a P/E/G ratio of 1.87 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price target on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Canaccord Genuity Group increased their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Finally, Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.